Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a revised positive opinion confirming the positive benefit-risk profile for Tyverb, the company's new oral treatment for breast cancer.
Subscribe to our email newsletter
The positive opinion recommends grant of a conditional marketing authorization. The revised positive opinion has been issued following review by the CHMP of new data received in February 2008 from GSK arising from a standard pharmacovigilance evaluation of clinical trial and post-marketing data.1 The CHMP has confirmed that these data do not essentially change the positive benefit-risk profile for lapatinib in its proposed indication.
Upon grant of the conditional marketing authorization by the European Commission, lapatinib, in combination with capecitabine, will be indicated for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress ErbB2 (HER2).